Press Releases

Date	Title
Mar 02, 2023	Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update - Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No
Feb 28, 2023	Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference DURHAM, N.C. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will participate
Feb 23, 2023	Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023 DURHAM, N.C. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on
Jan 05, 2023	Chimerix to Present at 41st Annual J.P. Morgan Healthcare Conference DURHAM, N.C. , Jan. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman , Chief Executive Officer, will present a

Print
Email Alerts
RSS Feeds
Search
Share